IL13 and poikiloderma with neutropenia: The role of type 2 inflammation is of interest in PN, given that there have been several off-label reports of the efficacy of treatment response with dupilumab, an IL-4 receptor α inhibitor that prevents IL-4 and IL-13 signaling (6).